Sarah A Anderson, Djamel Harbi, Diana Oramas Mogrovejo, Antoinette D Floyd, Isam-Eldin Eltoum, Huma Fatima, Frida Rosenblum, Manuel Lora Gonzalez, Diana Lin, Alexander C Mackinnon, Gene P Siegal, Thomas Winokur, Ceren Yalniz, Lei Huo, Shuko Harada, Xiao Huang
Introduction PD-L1 expression is the most widely-used predictive marker for immune checkpoint inhibitor (ICI) therapy in patients with lung adenocarcinoma. However, the current understanding of the association between PD-L1 expression and treatment response is suboptimal. A significant percentage of patients have only a cytological specimen available for clinical management. Therefore, it is relevant to examine the impact of molecular features on PD-L1 expression in cytological samples and how it might correlate with a therapeutic response...
July 26, 2023: Acta Cytologica